The Stamford, Connecticut-based firm, which has not been accused of any wrongdoing, made the money after a former portfolio manager illegally traded on a tip that Axcan Pharma would be acquired.
Read more: Hedge fund Diamondback to pay $1 million to settle insider case — Reuters
